阿布昔替尼片一个疗程几盒？

Abxitinib tablets are an oral Janus kinase (JAK) inhibitor that selectively inhibits JAK1 activity and blocks inflammatory signaling pathways, thereby alleviating the symptoms of immune-mediated diseases such as atopic dermatitis. It has been marketed in many countries around the world, including China. This article will introduce in detail the number of boxes required for a course of treatment of Abxitinib tablets, contraindications and pharmacokinetics to help patients better understand and use this drug.

How many boxes of Abxitinib tablets per treatment course

The number of treatment boxes depends on the patient’s medication dosage and treatment cycle. Understanding the specific medication needs can help patients plan their purchases and medication plans in advance.

Calculation of conventional dosage and course of treatment

The conventional recommended dosage of Abxitinib tablets is 100 mg once a day, with a specification of 100 mg*14 tablets/box. One box can meet the medication needs for two weeks. If a course of treatment is 12 weeks, the patient needs 6 boxes of medication.

Number of treatment boxes under high dose requirements

For patients who require higher doses, such as 200mg per day, the dosage will be doubled. Also taking 12 weeks as a treatment course, patients need 12 boxes of medicines. If high-dose treatment is initially used for 12 weeks and then adjusted to 100 mg for maintenance, 12 boxes will be required in the first 12 weeks, and the subsequent dosage will be halved.

Dose adjustment for special populations

For patients with slow metabolizers of CYP2C19 or those using strong CYP2C19 inhibitors, the recommended dose is 50 mg once daily. In this case, a box of 14 tablets can meet the medication needs for 28 days, and 3 boxes are required for a 12-week treatment course.

The number of treatment boxes of Abxitinib tablets varies depending on the dose and treatment cycle. Patients should plan their medication reasonably according to the doctor's advice and their own situation.

Contraindications of Abxitinib Tablets

Although Abxitinib Tablets is effective, it is not suitable for all patients. Understanding its contraindications is critical to safe use.

Contraindicated in patients with severe infections

Abxitinib tablets may increase the risk of infection, so patients with active severe infections (including local infections) should avoid use. For patients with chronic or recurrent infections, medications should be used with caution after a doctor evaluates the risks and benefits.

Use with caution in patients with specific diseases

Abxitinib tablets are contraindicated in patients with active tuberculosis, hepatitis B or hepatitis C. In addition, use is not recommended for patients with severe renal impairment (eGFR <30mL/min) and severe hepatic impairment (Child Pugh class C).

Drug interaction contraindications

When abuxitinib tablets are used together with strong CYP2C19 inhibitors, the dose needs to be adjusted to avoid adverse reactions. At the same time, it is not recommended to use it in combination with other JAK inhibitors or immunosuppressants to avoid increasing risks.

The contraindications of Abxitinib tablets involve many aspects such as infection, liver and kidney function, and drug interactions. Patients need to comprehensively evaluate their own conditions before taking the drug.

Pharmacokinetics of Abxitinib Tablets

The pharmacokinetic properties determine the absorption, distribution, metabolism and excretion process of the drug in the body, directly affecting the efficacy and safety of the drug.

Absorption and Distribution

Abxitinib tablets are rapidly absorbed after oral administration, and the plasma concentration reaches a steady state within 48 hours. Food has no significant effect on drug absorption, and patients can take it with food or on an empty stomach. The drug is widely distributed in the body and has a high binding rate to plasma proteins.

Metabolism and excretion

Abxitinib tablets are mainly metabolized by CYP2C19 and CYP2C9 enzymes to generate active metabolites M1 and I2. Patients with CYP2C19 slow metabolizers have reduced drug clearance and need to adjust the dose to avoid adverse reactions. Drugs and their metabolites are excreted primarily through urine and feces.

Pharmacokinetics in special populations

No dose adjustment is required in patients with mild or moderate hepatic impairment, but use should be avoided in patients with severe hepatic impairment. Patients with renal impairment need to adjust the dose according to the eGFR value, and the medication is not recommended for patients with severe renal impairment.

The pharmacokinetic properties of Abxitinib tablets provide a scientific basis for its medication regimen. Patients should strictly follow the doctor’s instructions when taking medication.